{"filing":{"accession_number":"0001649094-26-000026","cik":"0001649094","ticker":"PCVX","company_name":"Vaxcyte, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"pcvx-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000026/pcvx-20260617.htm"},"events":[{"id":13160,"run_id":11680,"accession_number":"0001649094-26-000026","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses the appointment of Moncef Slaoui to the Board as a Class II director effective immediately on June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee. While the section also mentions Jacks Lee's retirement from the Board and his entry into a consulting agreement, the principal disclosed action centers on the new director appointment. Board composition changes are material to investors' assessment of governance and strategic direction.","company_name":"Vaxcyte, Inc.","ticker":"PCVX","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10226,"accession_number":"0001649094-26-000026","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Moncef Slaoui to the Board as a Class II director effective immediately on June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee. While the section also mentions Jacks Lee's retirement from the Board and his entry into a consulting agreement, the principal disclosed action centers on the new director appointment. Board composition changes are material to investors' assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:10:16.291912+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10226,"accession_number":"0001649094-26-000026","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Moncef Slaoui to the Board as a Class II director effective immediately on June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee. While the section also mentions Jacks Lee's retirement from the Board and his entry into a consulting agreement, the principal disclosed action centers on the new director appointment. Board composition changes are material to investors' assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:10:16.291912+00:00","company_name":"Vaxcyte, Inc.","ticker":"PCVX","filing_date":"2026-06-23"}]}